Cite
MLA Citation
M. Martin et al.. “Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial.” Breast, vol. 56, n.d., pp. S19–. http://access.bl.uk/ark:/81055/vdc_100123988074.0x000024